- Home
- CRDL vs PBYI Comparison
CRDL vs PBYI Comparison
Compare CRDL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- PBYI
- Stock Information
- Founded
- CRDL 2017
- PBYI 2010
- Country
- CRDL Canada
- PBYI United States
- Employees
- CRDL N/A
- PBYI N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- PBYI Health Care
- Exchange
- CRDL Nasdaq
- PBYI Nasdaq
- Market Cap
- CRDL 104.5M
- PBYI 153.2M
- IPO Year
- CRDL N/A
- PBYI N/A
- Fundamental
- Price
- CRDL $1.25
- PBYI $3.09
- Analyst Decision
- CRDL Strong Buy
- PBYI Strong Buy
- Analyst Count
- CRDL 3
- PBYI 1
- Target Price
- CRDL $9.00
- PBYI $7.00
- AVG Volume (30 Days)
- CRDL 328.6K
- PBYI 754.5K
- Earning Date
- CRDL 11-14-2024
- PBYI 02-27-2025
- Dividend Yield
- CRDL N/A
- PBYI N/A
- EPS Growth
- CRDL N/A
- PBYI 492.79
- EPS
- CRDL N/A
- PBYI 0.47
- Revenue
- CRDL N/A
- PBYI $243,569,000.00
- Revenue This Year
- CRDL N/A
- PBYI N/A
- Revenue Next Year
- CRDL N/A
- PBYI N/A
- P/E Ratio
- CRDL N/A
- PBYI $6.63
- Revenue Growth
- CRDL N/A
- PBYI 6.30
- 52 Week Low
- CRDL $0.96
- PBYI $2.23
- 52 Week High
- CRDL $3.12
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- CRDL 35.65
- PBYI 49.17
- Support Level
- CRDL $1.23
- PBYI $2.92
- Resistance Level
- CRDL $1.51
- PBYI $4.06
- Average True Range (ATR)
- CRDL 0.10
- PBYI 0.29
- MACD
- CRDL 0.01
- PBYI 0.01
- Stochastic Oscillator
- CRDL 14.75
- PBYI 27.07
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.